Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Sovaldi (sofosbuvir) is a cost-effective treatment option for hepatitis C among the prison population when compared with other options.
Staging liver fibrosis among those with hepatitis C virus and only treating advanced cases is not cost-effective compared with treating all.
With interferon quickly becoming a thing of the past, what kind of side effects still remain in the new hepatitis C regimens--and how do you r...
As hepatitis C treatment undergoes a revolution, the doors are swinging wide open for people coinfected with HIV to be cured of hep C.
A panel of medical experts in California has lambasted Gilead Sciences for its exorbitant pricing its new hepatitis C treatment, Sovaldi (sofo...
Daclatasvir and Sovaldi, given with or without ribavirin, cured between 92 and 100 percent of people with genotypes 1, 2 and 3 of hepatitis C.
With the FDA approval of Sovaldi and Olysio, many people with hepatitis C, including those coinfected with HIV, will likely line up for...
A recent liver conference made it more clear than ever that the means to blow hepatitis C off the map is just within reach.
Gilead Sciences has sued Merck to defend its control of sofosbuvir, a late-stage experimental drug for the hepatitis C virus.
Victrelis, when added to interferon and ribavirin, improves cure rates of hepatitis C and does not raise major treatment risks in those coinfe...
The FDA has sped up the development and approval process for promising new hepatitis C therapies from three different companies.
There are differences between Incivek (telaprevir) and Victrelis (boceprevir) in treatment for Hepatitis C, specifically side effects and leng...
The FDA has given Janssen Research and Development priority review status for its investigational hepatitis C therapy simeprevir.
Preparing for a great revolution in hepatitis C care, major pharmaceutical companies are in a mad dash toward achieving blockbuster status.
Victrelis or Incivek-based triple therapy for hepatitis C virus resulted in low cure rates and high rates of serious side effects among those...
Treating hepatitis C post-liver transplant yields moderately good results with Victrelis (boceprevir) or Incivek (telaprevir)-based triple the...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.